Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

RU-486 or mifepristone is best known as an antiprogestin and an abortifacient, but it has broad medical applicability. The drug is also a potent blocker of corticosteroid receptors, and it has shown promise in the treatment of breast cancer, inoperable meningioma, and cushing's disease. Cushing's is a model for the symptomatology of aging which may involve enhanced response to corticosteroid. RU-486 has reversed the osteoporosis, thinning of skin, muscle atrophy, obesity, adult onset diabetes, depression, hypertension, and immunosuppression associated with this disease. RU-486 may be of value in aiding cervical dilation, lactation, and the treatment of endometriosis. In addition, breast, bowel, kidney tumors, hepatomas, endometrial cancer, and fibrosarcomas can show corticosteroid dependency, suggesting that RU-486 may have clinical value against inoperable tumors. In a preliminary 1987 phase I study, in estrogen-positive, chemotherapy-refractory breast cancer patients in Montpelier, France, Ru-486 produced objective tumor regression (6 of 22) that was prolonged (3 months) in 4 patients. Clinical relief of bone pain was observed in 7 of 23 patients with a decline in carcinoembryonic antigen (CEA) tumor makers in 8 patients. Growing in vitro data also show that RU-486 can directly inhibit breast cancer cell proliferation. RU-486 has application for HIV infection, based on data that there is a serum factor in AIDS patients that enhances corticosteroid lympholysis. IN addition, the immune restorative action of RU-486 suggests that it could counteract the immunosuppression seen in aging, in cancer, or in viral or stress-related disease, which has recently focused clinical attention on its potential in the treatment of senile dementia and depression. Scientific conferences and workshops are needed to alert scientists, physicians, and the public to the potential medical benefits of this drug.
 ...
PMID:RU 486: how abortion politics have impacted on a potentially useful drug of broad medical application. 150 96

Transabdominal ultrasonic scanning was used to examine 48 patients with endometrial carcinoma; 39 of them were later operated on, and 5 of these examined in various periods after surgery. No image of the median uterine echo in women with clinical symptoms of cancer of the body of the uterus or thinning of the median structure may evidence in favor of poorly-differentiated adenocarcinoma. The authors emphasize the usefulness of echography in the diagnosis of the depth of the tumor invasion into the myometrium, detection of the recurrences, and pay special attention to imaging the uterine myoma and other associated diseases of the genitals in these patients.
 ...
PMID:[Ultrasonic diagnosis during the treatment of patients with cancer of the uterine body]. 175 99

The junctional zone endometrium (JZE) is a compacted layer of smooth muscle cells with little extracellular matrix. The innermost myometrium adjacent to the endometrium, JZE is best visualized and evaluated on T2-weighted magnetic resonance imaging (MRI) and two-dimensional/three-dimensional transvaginal ultrasound (TVUS) scanning. Increased thickness of JZE >12 mm on MRI images has been associated with myometrial and subendometrial pathologic conditions, such as, adenomyosis, and is considered a poor prognostic factor for implantation. Gonadotrophin-releasing hormone analogue (GnRHa) has been proposed as a treatment for adenomyosis and fibroids larger than 7 cm, and overall improvement in symptoms and disease progression were attributed to JZE thinning after GnRHa treatment. JZE contractility and frequency of contractions are affected by ovarian hormone cyclic activity and pathologic changes adjacent to JZE, such as fibroids and polyps. However, JZE contractility is not evaluated by TVUS during gynecological examinations because guidelines do not exist and the process is time consuming. The present data indicate that JZE is an important part of the nongravid uterus anatomy, structure, and functionality. When more evidence is available, the morphologic features, thickness, and contractility of JZE may potentially be used as markers for diagnosis and prognosis of normal and abnormal uterine function, for early stages of pregnancy, and possibly for early detection of endometrial cancer. A new tool for JZE measurements should be further investigated to fill this clinical gap. Key Message: JZE is an important component of the nongravid uterus anatomy, structure, and functionality. The thickness and contractility of JZE could potentially be used as markers for diagnosis and prognosis of normal and abnormal uterine function, early stages of pregnancy, and early detection of endometrial cancer. A new tool for JZE measurements should be further investigated.
 ...
PMID:Junctional Zone Endometrium Morphological Characteristics and Functionality: Review of the Literature. 3196 33